Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SCH 66336
Lonafarnib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lonafarnib plus Anastrozole | EXPERIMENTAL | Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib |
| Placebo plus Anastrozole | ACTIVE_COMPARATOR | Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo |
| Name | Type | Description |
|---|---|---|
| Lonafarnib | DRUG | - |
| Placebo | DRUG | - |
| anastrozole | DRUG | - |
Inclusion Criteria: * Postmenopausal women who have histologically-confirmed breast cancer with the following characteristics: * estrogen and/or progesterone receptor positive, * locally advanced disease * distant metastatic disease, stage 4 * Subjects eligible for single-agent treatment wit...
Top 20 of 87 competitors
Lonafarnib has been studied in breast cancer. It was evaluated in a Phase 2 trial in combination with anastrozole for the treatment of advanced breast cancer in female patients. The trial compared anastrozole plus Lonafarnib against anastrozole plus placebo.
Lonafarnib targets the enzymes FNTA and FNTB, which are farnesyltransferase subunits. It acts as an inhibitor of these enzymes. This mechanism is being investigated in oncology, specifically in breast cancer.
Lonafarnib is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is responsible for its clinical development.
Lonafarnib is in Phase 2 clinical development for breast cancer. It is an investigational small molecule and has not been approved by the FDA for this indication.
Lonafarnib has been studied in one completed Phase 2 trial, NCT00081510, titled Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer. The trial enrolled 110 female patients and was randomized, double-blind, and active-controlled.
Yes, Lonafarnib is also known as SCH 66336. This alternative name appears in the title of its clinical trial, NCT00081510, which refers to the drug as Lonafarnib (SCH 66336).